Reveris Therapeutics is a pre-clinical stage pharmaceutical company developing novel therapeutics for triple negative breast cancer (TNBC). More than 34,500 women are diagnosed with TNBC in the United States each year, yet no targeted therapy currently exists for TNBC.
Reveris Therapeutics aims to develop highly efficacious, nontoxic small molecule inhibitors to treat TNBC. Our unique approach selectively targets and kills susceptible cancer cells, but not normal cells, promising improved efficacy and fewer side effects for patients. Reveris’ established team, network of collaborators and singular focus is enabling Reveris to advance our pioneering technology toward the clinic.Meet the Team →